To reach the next value inflection
LicenseRx asset brief
Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection
Probability of Success
22% · grade C · Medium data confidence
Model PoS 22% (grade C, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
57
Preclinical; PK data.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
70
Infectious Disease -- active buyer appetite.
Competitive whitespace (12%)
68
Average room to differentiate vs. incumbents.
Translational evidence (12%)
46
No translational evidence keywords in the public summary -- lab-stage claim.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →